Amgen stock moves lower after Rep Luz Rivas joins Amgen Foundation students

Traders Union
All News
Companies
Amgen dips 0.19% today

Highlights

AMGN remains under short- and medium-term pressure, trading below key moving averages while holding above strong long-term support.
Momentum indicators reflect cautious sentiment with a weak trend and mild downside bias, but recent gains show short-term recovery from weekly lows.
AMGN is likely to consolidate between $346 and $362 next week, with a breakout above $362 suggesting renewed bullish momentum.

AMGN is trading at $353.27, which is below both the 20-day SMA ($366.94) and 50-day SMA ($360.82) but remains well above the 200-day SMA ($317.52), signaling short- and medium-term selling pressure but firm long-term support. The Ichimoku Kijun on D1 is at $368.17, positioning immediate resistance above the current price; near-term support comes in at the 100-day SMA ($344.43) and 200-day SMA ($317.52), while near-term resistance is set by the 50-day SMA ($360.82) and Ichimoku Kijun ($368.17) as key resistance.

Momentum on D1 is subdued, with the MACD indicating a bearish bias and the ADX at 18.18, suggesting a weak trend. RSI stands at 42.48 with a Sell signal, and the CCI is also negative, both pointing to mild downside momentum, while the Stoch RSI is neutral. BBP at -0.68 highlights dominance by sellers, confirming bearish intraday sentiment. AMGN has risen $5.78 (1.66%) over the past week, moving up from $347.49, with the price now positioned in the upper part of the weekly range. Weekly volatility stands at 3.75%. Performance this week reflects a recovery from the lows, but D1 momentum remains cautious and slightly conflicted by weak daily oscillators versus the positive weekly move.

For the coming week, the expected price range is $346.00 to $362.00, keeping within roughly ±5% of the current price and well above the 52-week low ($261.43) yet below the 52-week high ($391.29). Based on the W1 indicators—3 out of 4 major signals (RSI, ADX, MACD, MA-50) are Buy or Strong Buy—the probability of a further price increase is very high (more than 80%), making a decline much less likely. Baseline scenario: AMGN is likely to consolidate between $346 and $362 as short-term bearish momentum battles longer-term support. A bullish scenario would see a breakout above $362, testing resistance near $368, while a bearish move below $346 could trigger a retreat toward $344 or into the lower $340s. The overall technical profile favors consolidation with an upward tilt, underpinned by robust long-term trend signals.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Amgen's future growth prospects hinge on whether new therapies like MariTide can compensate for steep declines expected from its legacy products facing biosimilar competition. With the evolving competitive landscape and ongoing trial milestones, the prevailing scenario calls for close monitoring of regulatory updates and major data releases that could impact sentiment and define the next directional move for Amgen shares.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.